Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Direkt zur Navigaton springen.
Direkt zum Inhalt springen.

Navigation/Suche

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Piccini, JP; Patel, MR; Steffel, J; Ferdinand, K; Van, Gelder, IC; Russo, AM; Ma, CS; Goodman, SG; Oldgren, J; Hammett, C; Lopes, RD; Akao, M; De, Caterina, R; Kirchhof, P; Gorog, DA; Hemels, M; Rienstra, M; Jones, WS; Harrington, J; Lip, GYH; Ellis, SJ; Rockhold, FW; Neumann, C; Alexander, JH; Viethen, T; Hung, J; Coppolecchia, R; Mundl, H; Caso, V, , OCEANIC-AF, Steering, Committee, and, Investigators, , OCEANIC-AF, Steering, Committee, and, Investigators.
Asundexian versus Apixaban in Patients with Atrial Fibrillation.
N Engl J Med. 2025; 392(1): 23-32. Doi: 10.1056/NEJMoa2407105
Web of Science PubMed FullText FullText_MUG

Study Group Mitglieder der Med Uni Graz:: Scherr Daniel
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: BACKGROUND: Stroke prevention with direct-acting oral anticoagulant agents in patients with atrial fibrillation confers a risk of bleeding and limits their use. Asundexian, an activated factor XI (XIa) inhibitor, is an oral anticoagulant that may prevent strokes with less bleeding. METHODS: In a phase 3, international, double-blind trial, we randomly assigned high-risk patients with atrial fibrillation in a 1:1 ratio to receive asundexian at a dose of 50 mg once daily or standard-dose apixaban. The primary efficacy objective was to determine whether asundexian is at least noninferior to apixaban for the prevention of stroke or systemic embolism. The primary safety objective was to determine whether asundexian is superior to apixaban with respect to major bleeding events. RESULTS: A total of 14,810 randomly assigned patients were included in the intention-to-treat population. The mean (±SD) age of the patients was 73.9±7.7 years, 35.2% were women, 18.6% had chronic kidney disease, 18.2% had a previous stroke or transient ischemic attack, 16.8% had received oral anticoagulants for no more than 6 weeks, and the mean CHA₂DS₂-VASc score (range, 0 to 9, with higher scores indicating a greater risk of stroke) was 4.3±1.3. The trial was stopped prematurely at the recommendation of the independent data monitoring committee. Stroke or systemic embolism occurred in 98 patients (1.3%) assigned to receive asundexian and in 26 (0.4%) assigned to receive apixaban (hazard ratio, 3.79; 95% confidence interval [CI], 2.46 to 5.83). Major bleeding occurred in 17 patients (0.2%) who received asundexian and in 53 (0.7%) who received apixaban (hazard ratio, 0.32; 95% CI, 0.18 to 0.55). The incidence of any adverse event appeared to be similar in the two groups. CONCLUSIONS: Among patients with atrial fibrillation at risk for stroke, treatment with asundexian at a dose of 50 mg once daily was associated with a higher incidence of stroke or systemic embolism than treatment with apixaban in the period before the trial was stopped prematurely. There were fewer major bleeding events with asundexian than with apixaban during this time. (Funded by Bayer; OCEANIC-AF ClinicalTrials.gov number, NCT05643573; EudraCT number, 2022-000758-28.).
Find related publications in this database (using NLM MeSH Indexing): Humans - administration & dosage; Atrial Fibrillation - drug therapy, complications; Pyrazoles - adverse effects, therapeutic use, administration & dosage; Pyridones - adverse effects, therapeutic use, administration & dosage; Female - administration & dosage; Male - administration & dosage; Aged - administration & dosage; Stroke - prevention & control; Double-Blind Method - administration & dosage; Hemorrhage - chemically induced; Aged, 80 and over - administration & dosage; Intention to Treat Analysis - administration & dosage; Factor Xa Inhibitors - adverse effects, therapeutic use, administration & dosage; Embolism - prevention & control, etiology; Anticoagulants - adverse effects, therapeutic use, administration & dosage; Middle Aged - administration & dosage; Administration, Oral - administration & dosage; Benzamides - administration & dosage; Hydrocarbons, Fluorinated - administration & dosage; Triazoles - administration & dosage